ABSI Company Profile and Key Details

Absci Corporation has 155.45 million shares outstanding. The public float is 143.43 million shares, elevated short interest at 28.10% of float. This equals 35.09 million shares. The short ratio is 7.88 days. Institutional investors hold 72.82% of the float. Insiders own 9.28%. Phoenix Venture Partners II LP holds 11.28 million shares, McClain Sean has 8.33 million shares and Redmile Group, LLC has 8.25 million shares. Over the past six months, insider transactions show net buying. They sold 44.26 thousand shares across 2 transactions.

ABSI has shown weak momentum, losing -14.71% over the past week and -35.98% over the past quarter, though year-to-date performance is down -16.91%. Short-term trend indicators are mixed aligned (SMA20 2.3%, SMA50 -9.81%, SMA200 -9.25%). The stock’s 14-day RSI is 48.85 (neutral), while the ATR of 0.2 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -46.25% below its high and over 39.8% above its low. Average 10-day trading volume of 6.74 million shares is significantly above the 3-month average of 4.08 million, indicating heightened recent market interest.

Absci Corporation generated EPS of -$0.90 over the past year. Five-year average earnings growth is -29.3%. Wall Street analysts project EPS growth of 9.94% annually over the next five years. The latest quarter delivered EPS of -$0.23. The next quarter is forecast at -$0.18. Next year's EPS is expected at $32.66. Analyst sentiment is bullish. Analyst rating data shows there are 2 Strong Buy ratings, 7 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $8.00 to $5.89. The high target offers 42.6% upside. The low target suggests 4.99% downside. The mean target is $7.03. This offers 25.31% upside. Absci Corporation earnings surprise history is a consistent trend of beating forecasts. The quarter that ended March 24, 2026, missed forecasts by 43.75%. The prior quarter beat by 5.26%. Over the last six quarters, Apple has recorded several small beats. These include 26.32% in November 12, 2024.

Absci Corporation last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.06. This means the shares are trading below this model’s fair value.

Absci Corporation (NASDAQ:ABSI) closed at $5.61 USD, losing -$0.01 (-0.18%) from the previous close of $5.62. The stock is currently within 5% of its 52-week high $2.24 and $5.75. With a market capitalization of about $872.06 million, Absci Corporation is classified as a small-cap and shows higher-than-market volatility (beta ~2.01). Key stats such as the average daily volume over the past year has been around 4.02 million shares, in line with its 52-week average. Headquartered in Vancouver, WA, Absci Corporation operates in the Healthcare sector and the Biotechnology industry. Led by CEO Sean McClain, the company employs approximately 156 people and listed since July 22, 2021. Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States.

Absci Corporation (NASDAQ:ABSI) shares are down -16.91% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Absci Corporation trading at a premium to the broader market with a P/E of -7.2. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $8.84, suggesting 57.58% upside. Our AI forecast model points to short-term strength (25.49% over two weeks), a medium-term fall (-35.83% over three months), and a longer-term gain (349.2% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Absci Corporation stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 25.49%, with price expected at $7.04 by May 19, 2026, within a range of $6.78 to $7.30 3-Month Outlook: Projected fall of -35.83%, reaching $3.60 by August 03, 2026, with a range of $2.91 to $3.91. 1-Year Outlook: Projected gain of 349.2%, with price at $25.20 by May 05, 2027, within a range of $19.20 to $35.73.

Absci Corporation trades at a P/E ratio of -7.2, slightly below the S&P 500 average, with a price-to-sales ratio of 305.9 and a price-to-book ratio of 4.38 trading at moderately above to book value. The P/FCF stands at -9.11, also below market averages.